A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

NCT07256912 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1266

Enrollment

OTHER

Sponsor class

Conditions

Vaccine Effectiveness
HPV Vaccination
Single Dose
Immunogenicity
Cervical Cancer Prevention
Quadrivalent HPV Vaccine

Interventions

BIOLOGICAL: quadrivalent HPV vaccine
BIOLOGICAL: quadrivalent HPV vaccine

Sponsor

International Agency for Research on Cancer